An Inlet Patch Case with Difficulty Swallowing

Heterotopic Gastric Mucosa (inlet patch) is a clinical entity, described firstly by Schmit as a congenital anomaly, char-acterized by settling of gastric mucosa in any part of the gastrointestinal mucosa. It causes various clinical symp-toms due to acid secretion. Our case is oberved rarelly in case of inlet patch

Some new generalizations for GA–convex functions

In this paper, firstly we prove an integral identity that one can derive several new equalities for special selections of n from this identity : Secondly, we established more general integral inequalities for functions whose second derivatives of absolute values are GA-convex functions based on this equality

Vitamin D Deficiency Might Contribute Fatigue and Disease Activity in Patients with Fibromyalgia

[No Abstract Available

OSTEOPROTEGERIN PLASMA CONCENTRATIONS ARE CORRELATED WITH FORCED EXPIRATORY VOLUME AT 1 SECOND (FEV1) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

[No Abstract Available

An Inlet Patch Case with Difficulty Swallowing

Heterotopik gastrik mukoza (inlet patch), ilk kez Schmidt tarafından tanımlanmış, gastrik mukozanın gastro intestinal sistemin herhangi bir yerine yerleşmesi ile karakterize, salgılanan asit nedeniyle çok değişik klinik bulgulara yol açan bir klinik antidedir. Olgumuz, nadir görülen bir semptom olan yutma güçlüğü ile başvurması nedeniyle sunulmuştur.Heterotopic Gastric Mucosa (inlet patch) is a clinical entity, described firstly by Schmit as a congenital anomaly, characterized by settling of gastric mucosa in any part of the gastrointestinal mucosa. It causes various clinical symptoms due to acid secretion. Our case is oberved rarelly in case of inlet patch

A Case of Choroid Plexus Papilloma with Rare Location Presenting with Impaired Consciousness

Naldemir, Ibrahim Feyyaz/0000-0002-0804-7378; kilicaslan, onder/0000-0002-9311-006XWOS: 000499969200016Intraventricular papillary neoplasms originating from the choroid plexus epithelium are called choroid plexus tumors (CPT). In pediatric patients. The most common findings in CPT are seizures, subarachnoid hemorrhage, focal neurological deficits, hydrocephalus and symptoms of increased intracranial pressure. A 4.5-month-old, previously healthy girl was admitted to our Pediatric Emergency Department with complaints of inadequate nutrition, vomiting and drowsiness in the last 2 days. The patient was admitted to the pediatric intensive care unit and saline loading treatment was initiated due to presumed dehydration caused by inadequate nutrition. As dehydration-related pathology was not detected, brain tomography scan was performed for possible cranial pathology and it revealed increased bilateral lateral ventricular diameters. As a result of magnetic resonance imaging results, the patient was diagnosed as having choroid plexus papilloma. After the shunt was inserted, the patient regained consciousness and an elective surgery was planned. Inadequate nutrition and drowsiness are the most common causes of admissions to pediatric emergency department, and these symptoms are usually due to dehydration. Cranial pathologies should be considered in patients who do not respond to fluid loading treatments and whose laboratory findings and vital signs are stable. As in our patient, the patients with choroid plexus papilloma should be evaluated clinically and shunt surgery should be performed firstly. Timing of surgery should be decided according to the effect and clinical status

Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Background The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that investigate the efficacy and safety of the new generation TKIs in real-world patients. Thus, we aimed to compare the efficacy and safety of the afatinib, an irreversible inhibitor of ErbB family receptor, and first-generation TKIs in real-world patients. Materials and methods We included advanced nonsmall cell lung cancer (NSCLC) patients who had EGFR exon 19del mutation and treated with afatinib or first-generation TKIs as upfront treatment between 2016 and 2020. All patient's information was collected retrospectively. The study cohort was divided as afatinib arm and erlotinib/gefitinib arm. Results A total of 283 patients at the 24 oncology centers were included. The 89 and 193 of whom were treated with afatinib and erlotinib/gefitinib, respectively. After 12.9 months (mo) of follow-up, the median PFS was statistically longer in the afatinib arm than erlotinib/gefitinib arm (19.3 mo vs. 11.9 mo, p: 0.046) and the survival advantage was more profound in younger patients (< 65 years). The 24-mo overall survival rate was 76.1% and 49.5% in the afatinib arm and erlotinib/gefitinib arm, respectively. Although all-grade adverse event (AE) rates were similar between the two arms, grade 3-4 AE rates were higher in the afatinib arm (30.7% vs. 15.2%; p: 0.004). Discussion In our real-world study, afatinib has superior survival outcomes despite worse toxicity profile as inconsistent with clinical study results and it is the good upfront treatment option for younger patients and elderly patients who have good performance status